Hemorrhoid Treatment in a Complete, Single-Use Kit
FAIRFIELD, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Kenwood Therapeutics, a
Division of Bradley Pharmaceuticals, Inc. (NYSE: BDY), announces the launch of
new, enhanced, prescription-only ANAMANTLE HC(R) (Lidocaine HCl 3% -
Hydrocortisone Acetate 0.5%) Cream Kit. ANAMANTLE HC(R) Cream Kit is a
hemorrhoid therapy that comes complete in a single-use kit.
Bradley developed new ANAMANTLE HC(R) Cream Kit in response to physician
demand for a hemorrhoid therapy that combines multiple components for patient
convenience and comfort. ANAMANTLE HC(R) Cream Kit is available in a box of 20
individually sealed, single-use kits, each consisting of one 7 gram tube of
ANAMANTLE HC(R) Cream and one single-use applicator for a sanitary approach to
treating hemorrhoids. Each single-use kit also contains one dye-free,
premoistened personal cleansing wipe with the cooling, soothing properties of
aloe.
ANAMANTLE HC(R) Cream Kit features ANAMANTLE HC(R) Cream, a light-
textured, non-greasy formula that provides lidocaine HCl to help alleviate
discomfort and itching resulting from inflamed, painful hemorrhoids,
hydrocortisone acetate that delivers vasoconstrictive and anti-inflammatory
action to reduce swelling, and a pH-balancing base that fosters a healing
environment. Additionally, ANAMANTLE HC(R) Cream Kit provides value,
delivering a full 10 days of therapy when used twice a day.
President and CEO, Daniel Glassman, stated, "Bradley Management constantly
seeks ways to enhance the Company's products to meet the needs of target
physician audiences and improve quality of life for their patients. The
introduction of ANAMANTLE HC(R) Cream Kit will provide patients with an
enhanced, single-use hemorrhoid therapy kit. ANAMANTLE HC(R) Cream Kit is the
only product on the market that delivers a convenient and sanitary solution
for hemorrhoid treatment, containing a single-use tube of anesthetic, anti-
inflammatory, pH-balancing cream, a single-use applicator and a personal
cleansing wipe."
Important Safety Information
ANAMANTLE HC(R) is contraindicated for those with fungal lesions, as well
as skin vaccinia, varicella or acute herpes simplex. ANAMANTLE HC(R) is also
contraindicated for patients taking Class I antiarrhythmic drugs. Care should
be taken in prescribing ANAMANTLE HC(R) for patients with impaired liver
function, significant liver disease or for the elderly or very ill. In case of
bleeding, patients should consult a doctor promptly. For external use only. Do
not use on children under 2 without consulting a doctor. Avoid ingestion or
contact with eyes, ears, mouth and nose. For additional Contraindications and
Warnings information, see Package Insert located on our web site.
Bradley Pharmaceuticals, Inc. (NYSE: BDY) was founded in 1985 as a
specialty pharmaceutical company marketing to niche physician specialties in
the U.S. and 38 international markets. Bradley's success is based on the
strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands,
Enhances these brands with line extensions and improved formulations and Grows
the products through promotion, advertising and selling activities to optimize
life cycle management. Bradley Pharmaceuticals is comprised of Doak
Dermatologics, specializing in topical therapies for dermatology and podiatry,
and Kenwood Therapeutics, providing gastroenterology, respiratory and other
internal medicine brands.
Important announcement:
Daniel Glassman will present at the Raymond James & Associates 26th Annual
Institutional Investors Conference, Monday, March 7, 2005 at 1:05 PM at the
Hyatt Regency Grand Cypress in Orlando, FL.
Daniel Glassman will present at the CIBC World Markets' Annual
Biotechnology & Specialty Pharmaceuticals Conference April 4-5, 2005 at The
Millennium Broadway Hotel in New York City.
Please visit Bradley Pharmaceuticals web site at:
http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or may occur
in the future, such as earnings estimates, other predictions of financial
performance, launches by Bradley of new products and market acceptance of
Bradley's products. Forward-looking statements are based on Bradley's
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond Bradley's control. These risks and uncertainties include
Bradley's ability to maintain sales of its products, successfully acquire,
develop, integrate, or sell new products or effectively react to other risks
and uncertainties described from time to time in Bradley's SEC filings, such
as fluctuation of quarterly financial results, estimation of product returns,
chargebacks, rebates and allowances, concentration of customers, reliance on
third party manufacturers and suppliers, litigation or other proceedings,
government regulation and stock price volatility. Further, Bradley cannot
accurately predict the impact on its business of the approval, introduction,
or expansion by competitors of generic or therapeutically equivalent or
comparable versions of Bradley's products or of any other competing products.
Bradley does not guarantee any forward-looking statement, and actual results
may differ materially from those projected. Bradley undertakes no obligation
to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
SOURCE Bradley Pharmaceuticals, Inc.
 back to top
Related links:
http://www.bradpharm.com
CONTACT:
Anthony Griffo, Investor Relations, Bradley
Pharmaceuticals, Inc., +1-973-882-1505, ext. 313
|
